Focus on Application, Approach, Type, Line of Therapy, Treatment Strategy, Country Data (15 Countries),and Competitive Landscape – Analysis and Forecast, 2023-2030
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 34.69%
The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, inc
1.1 Inclusion and Exclusion
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3.1 Data Sources
3.1.1 Primary Data Sources
3.1.2 Secondary Data Sources
3.2 Market Estimation Model
3.2.1 Considered Factors for Data Prediction and Modeling
3.2.2 Assumptions and Limitations
4.1 Introduction
4.2 Cancer Antigens
4.3 Targeting Cancer Neoantigen: A next wave of innovation in Oncology?
4.4 Neoantigen Cancer Vaccine Mechanism of Action
4.5 Types of Neoantigen Cancer Vaccines, by Product Type
4.5.1 Personalized neoantigens vaccines
4.5.2 Off-the-shelf Neoantigen vaccines
4.6 Types of Neoantigen Cancer Vaccine Market, by Neovaccine Types (Biological Platform)
4.6.1 Nucleic acid/DNA/mRNA Vaccines
4.6.2 Peptide Vaccines
4.6.3 Dendritic Cell–based Vaccines
4.7 Types of Neoantigen Cancer Vaccine, by Delivery Strategies
4.7.1 Lipid-Based Approaches
4.7.2 Peptide (SLP) Mediate Vaccine Delivery in Conjunction with an Adjuvant
4.7.3 Sequential immunization of Viral Prime and RNA Boost
4.7.4 Direct Injection of Unformulated mRNA Vaccines Encoding Neoepitopes
4.7.5 Other Approaches
4.8 Prediction Software for Neoantigens
4.8.1 Limitations of Neoantigen Prediction Process
4.9 Limitations of Neoantigen Cancer Vaccines
4.9.1 Lower Tumor Mutational Burden
4.9.2 Neoantigens Maturity
4.10 Future Prospects
4.10.1 Multi-Epitope Vaccination
4.10.2 Combination with Other Kinds of Immunotherapies and Conventional Treatments
4.10.3 Combination with Traditional Cancer Therapies
5.1 Overview of Regulatory Pathway for Neoantigen Cancer Vaccines
5.1.1 U.S. FDA Guidelines for BLA Submission
5.1.2 EMA Biologics License Application Process
5.1.2.1 Centralized Procedure
5.1.2.2 Decentralized Procedure
5.1.2.3 Mutual-Recognition Procedure
5.2 Regulatory Challenges
5.3 Successful Regulatory Strategies
6.1 Growth Share Analysis
6.1.1 Growth Share Matrix by Oncology Specialty
6.1.2 Growth Share Matrix by Product Type
6.1.3 Growth Share Matrix by Region
6.1.4 Growth Share Matrix by Line of Therapy
6.1.5 Growth Share Matrix by Type of Therapy
6.1.6 Growth Share Matrix by Type of Neovaccine
6.2 FDA Review Landscape
6.3 Patent Landscape
7.1 Overview
7.2 Emerging and Current Market Trends
7.3 Market Drivers
7.3.1 Increasing Global Prevalence of Cancers
7.3.2 Increase in Adoption of Personalized Medicine to Tailor Patient’s Treatment on an Individual Level
7.3.3 Significant External Funding for Executing Research and Development Exercise
7.4 Market Restraints
7.4.1 Higher Cost of Personalized Cancer Vaccines
7.4.2 Hurdles in Clinical Development and Optimization Process
7.4.3 Uncertain Reimbursement Scenario
7.4.4 Payer Uncertainty and Outcome-Based Pricing
7.4.5 High Capital Requirement Hampering the Expansion of Global Reach
7.5 Market Opportunities
7.5.1 Treatment Gaps
7.5.2 Reduced Turnaround Time and Cost
7.5.3 Partnerships and Collaboration Between Various Healthcare Stakeholders
7.5.4 Data Analytics
8.1 Emerging Neoantigen Vaccines
8.2 Clinical Trials Heat Map
8.3 Pipeline Analysis
8.3.1 By Phase of Development
8.3.2 By Type of Therapy
8.3.3 By Product Type
8.3.4 By Treatment Strategy
8.3.5 By Type of Neovaccine
8.3.6 By Delivery Approach
8.3.7 By Line of Therapy
8.3.8 By Oncology Specialty
8.3.9 By Route of Administration
8.3.10 By Core Product Status
8.3.11 By Neoantigen Payload
9.1 Key Strategies and Developments
9.1.1 Synergistic Activities
9.1.2 Funding and Expansion Activities
9.1.3 Mergers and Acquisitions
9.2 Partnership and Financing Opportunities
10.1 Personalized Neoantigen Vaccines
10.2 Off-the-Shelf Neoantigen Vaccines
11.1 Nucleic Acid/DNA/mRNA Vaccines
11.1.1 DNA Vaccines
11.2 RNA Vaccines
11.3 Peptide Vaccines
11.4 Dendritic Cell–Based Vaccines
12.1 First Line Neovaccines Regimens
12.2 Second Line Neovaccine Regimens
12.3 Later Lines Neovaccines Regimens
13.1 Mono Therapeutic Regimens
13.2 Combinatorial Regimens
14.1 Hematological Malignancies
14.2 Melanoma
14.3 Breast Cancer
14.4 Gastrointestinal Cancer
14.5 Lung Cancer
14.6 Solid Tumors
14.7 Urinary System Cancer
14.8 Prostate Cancer
14.9 Head and Neck Cancers
14.10 Gynecologic Cancers
14.11 Brain Cancer
15.1 Overview
15.2 North America
15.2.1 Market Size and Forecast
15.2.2 Key Developments
15.3 Canada
15.3.1 Market Size and Forecast
15.3.2 Key Developments
15.4 Europe
15.4.1 Germany
15.4.1.1 Market Size and Forecast
15.4.1.2 Key Developments
15.4.2 France
15.4.2.1 Market Size and Forecast
15.4.2.2 Key Developments
15.4.3 U.K.
15.4.3.1 Market Size and Forecast
15.4.3.2 Key Developments
15.4.4 Italy
15.4.4.1 Market Size and Forecast
15.4.5 Spain
15.4.5.1 Market Size and Forecast
15.4.6 Rest-of-Europe
15.4.6.1 Market Size and Forecast
15.4.6.2 Key developments
15.5 Asia-Pacific
15.5.1 Japan
15.5.1.1 Market Size and Forecast
15.5.1.2 Key Developments
15.5.2 China
15.5.2.1 Market Size and Forecast
15.5.2.2 Key developments
15.5.3 Australia
15.5.3.1 Market Size and Forecast
15.5.4 South Korea
15.5.4.1 Market Size and Forecast
15.5.5 Israel
15.5.5.1 Market Size and Forecast
15.5.6 Rest-of-Asia-Pacific
15.5.6.1 Market Size and Forecast
15.5.6.2 Key Developments
16.1 Moderna Therapeutics
16.1.1 Company Overview
16.1.2 Role of Moderna Therapeutics in the Global Neoantigen Cancer Vaccine Market
16.1.3 Technology and Capabilities
16.1.4 Financials
16.1.5 Key Insights About Financial Health of the Company
16.1.6 SWOT Analysis: Moderna Therapeutics
16.2 F. Hoffmann-La Roche Ltd
16.2.1 Company Overview
16.2.2 Role of F. Hoffmann-La Roche Ltd in the Global Neoantigen Cancer Vaccine Market
16.2.3 Technology and Capabilities
16.2.3.1 Technology Platform
16.2.3.2 Manufacturing
16.2.4 Financials
16.2.5 Key Insights About Financial Health of the Company
16.2.6 SWOT Analysis: F. Hoffmann-La Roche
16.3 AstraZeneca plc
16.3.1 Company Overview
16.3.2 Role of AstraZeneca plc in the Global Neoantigen Cancer Vaccine Market
16.3.3 Financials
16.3.4 Key Insights About Financial Health of the Company
16.3.5 SWOT Analysis: AstraZeneca
16.4 Agenus
16.4.1 Company Overview
16.4.2 Role of Agenus in the Global Neoantigen Cancer Vaccine Market
16.4.3 Technology and Capabilities
16.4.3.1 Technology Platforms
16.4.3.2 Manufacturing
16.4.3.3 Adjuvant
16.4.4 Financials
16.4.5 Key Insights About Financial Health of the Company
16.4.6 SWOT Analysis: Agenus
16.5 OSE Immunotherapeutics
16.5.1 Company Overview
16.5.2 Role of OSE Immunotherapeutics in the Global Neoantigen Cancer Vaccine Market
16.5.3 Technology and Capabilities
16.5.3.1 Technology Platforms
16.5.3.2 Manufacturing
16.5.4 Financials
16.5.5 Key Insights About Financial Health of the Company
16.5.6 SWOT Analysis: OSE Immunotherapeutics
16.6 Advaxis
16.6.1 Company Overview
16.6.2 Role of Advaxis in the Global Neoantigen Cancer Vaccine Market
16.6.3 Technology and Capabilities
16.6.3.1 Technology platform
16.6.4 Manufacturing
16.6.5 Financials
16.6.6 Key Insights About Financial Health of the Company
16.6.7 SWOT Analysis: Advaxis
16.7 Medigene
16.7.1 Company Overview
16.7.2 Role of Medigene in the Global Neoantigen Cancer Vaccine Market
16.7.3 Technology and Capabilities
16.7.3.1 Technology Platform
16.7.3.2 Manufacturing
16.7.4 Financials
16.7.5 Key Insights About Financial Health of the Company
16.7.6 SWOT Analysis: Medigene
16.8 Neon Therapeutics
16.8.1 Company Overview
16.8.2 Role of Neon Therapeutics in the Global Neoantigen cancer Vaccine Market
16.8.3 Technology and Capabilities
16.8.3.1 Technology Platforms
16.8.4 Manufacturing
16.8.5 Key Insights About Financial Health of the Company
16.8.6 SWOT Analysis: Neon Therapeutics
16.9 Genocea Biosciences
16.9.1 Company Overview
16.9.2 Role of Genocea Biosciences in the Global Neoantigen Cancer Vaccine Market
16.9.3 Technology and Capabilities
16.9.3.1 Technology Platform
16.9.3.2 Manufacturing Capabilities
16.9.4 SWOT Analysis: Genocea Biosciences
16.10 Immunovative Therapies
16.10.1 Company Overview
16.10.2 Role of Immunovative Therapies in the Neoantigen Cancer Vaccine Market
16.10.3 Technology and Capabilities
16.10.3.1 Technology Platform
16.10.3.2 Manufacturing
16.10.4 SWOT Analysis: Immunovative Therapies
16.11 Gritstone Oncology
16.11.1 Company Overview
16.11.2 Role of Gritstone Oncology in the Neoantigen Cancer Vaccine Market
16.11.3 Technology and Capabilities
16.11.3.1 Technology Platform
16.11.3.2 Manufacturing
16.11.4 SWOT Analysis: Gritstone Oncology
16.12 Nouscom
16.12.1 Company Overview
16.12.2 Role of Nouscom in the Global Neoantigen Cancer Vaccine Market
16.12.3 Technology and Capabilities
16.12.3.1 Technology Platform
16.12.3.2 Manufacturing
16.12.4 SWOT Analysis: Nouscom
16.13 NantBioScience
16.13.1 Company Overview
16.13.2 Role of NantBioScience in the Neoantigen cancer vaccine Market
16.13.3 SWOT Analysis: NantBioScience
16.14 Immunovaccine
16.14.1 Company Overview
16.14.2 Role of Immunovaccine in the Neoantigen Cancer Vaccine Market
16.14.3 SWOT Analysis: Immunovaccine
16.15 BioLineRx
16.15.1 Company Overview
16.15.2 Role of BioLineRx in the Neoantigen Cancer Vaccine Market
16.15.3 SWOT Analysis: BioLineRx
Table 4.1: Implications of PCV’s
Table 4.2: Implications of Off-The-Shelf NCV
Table 4.3: Implications of DNA and RNA Vaccines
Table 4.4: Implications of Peptide Vaccines
Table 4.5: Implications of DC Vaccines
Table 4.6: Prediction Software Utilized by Various Companies
Table 6.1: Neoantigen Cancer vaccines Designation Landscape, by 2019
Table 6.2: Neoantigen Cancer Vaccines Patent Landscape, by 2019
Table 8.1: Key Neoantigen Vaccines in Clinical Development Phase 1, 2 & 3, by 2019
Table 8.2: Neoantigen Vaccines, by Therapy Type
Table 8.3: Neoantigen Vaccines, by Treatment Strategy
Table 8.4: Neoantigen Vaccines, by Line of Therapy
Table 8.5: Neoantigen Vaccines, by Route of Administration
Table 8.6: Neoantigen Vaccines, by Core Product Type (Licensed Products/ Technology only)
Table 8.7: Neoantigen Vaccines, by Payload
Table 9.1: Neoantigen Vaccines: Companies Status
Table 14.1: Neoantigen Vaccines for Hematological Malignancies
Table 14.2: Neoantigen Vaccines for Melanoma: Pipeline Products
Table 14.3: Neoantigen Vaccines for Breast Cancer: Pipeline Products
Table 14.4: Neoantigen Vaccines for GI Cancer: Pipeline Products
Table 14.5: Neoantigen Vaccines, by Lung Cancer: Pipeline Products
Table 14.6: Neoantigen Vaccines for Solid Tumors: Pipeline Products
Table 14.7: Neoantigen Vaccines for Urinary System Cancers: Pipeline Products
Table 14.8: Neoantigen Vaccines for Head and Neck Cancers: Pipeline Products
Table 14.9: Neoantigen Vaccines for Gynecologic Cancer: Pipeline Products
Table 14.10: Neoantigen Vaccines for Brain Cancer: Pipeline Products
Table 15.1: Key Developments
Table 15.2: Key Developments
Table 15.3: Key Developments
Table 15.4: Key Developments
Table 15.5: Key Developments
Table 15.6: Key Developments
Table 15.7: Key Developments
Table 15.8: Key Developments
Table 15.9: Key Developments
Table 17.1: Anticipated Milestones (Launch and Trials Outcomes Related to Neovaccines)
Figure 1: Impact Analysis of Market Drivers and Market Challenges on the Global Neoantigen Cancer Vaccine Market
Figure 2: Global Neoantigen Cancer Vaccine Market, By Product Type, 2023 vs. 2030 ($Million)
Figure 3: Global Neoantigen Cancer Vaccine Market, By Type of Neovaccine, 2023 vs. 2030 ($Million)
Figure 4: Global Neoantigen Cancer Vaccine Market, By Oncology Specialty, 2023 vs. 2030 ($Million)
Figure 5: Global Neoantigen Cancer Vaccine Market, By Line of Therapy, 2023 vs. 2030 ($Million)
Figure 6: Global Neoantigen Cancer Vaccine Market Snapshot
Figure 2.1: Global Neoantigen Cancer Vaccine Market Segmentation
Figure 2.2: Global Neoantigen Cancer Vaccine Existing Pipeline Segmentation
Figure 3.1: Global Neoantigen Cancer Vaccine Market Research Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3: Step by Step Approach
Figure 4.1: Step by Step Process for Neoantigen Vaccine Development
Figure 4.2: Type of Cancer Antigens
Figure 4.3: Specialized Therapies Segmentation in U.S.
Figure 4.4: NCV Mechanism of Action
Figure 4.5: Factors Affecting Neoantigen Prediction Process
Figure 4.6: Future Prospects
Figure 5.1: U.S. FDA Review Timeline
Figure 5.2: EMA Review Timeline
Figure 6.1: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Application), 2023-2030
Figure 6.2: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Product Type), 2023-2030
Figure 6.3: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Region), 2023-2030
Figure 6.4: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Line of Therapy), 2023-2030
Figure 6.5: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Type of Therapy), 2023-2030
Figure 6.6: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine), 2023-2030
Figure 6.7: Neoantigen Cancer Vaccines Designation Landscape
Figure 6.8: Share of Patents (by Ownership), 2016-2019
Figure 7.1: Number of Deaths due to Different Cancer Types, Million, 2018
Figure 7.2: Global Cancer Incidence in (Million), 2018
Figure 7.3: Neo-vaccines Funding and Expansion Activities Breakout (January 2016- September 2019)
Figure 7.4: Overall Financing Raised by Emerging Neo-Vaccines Companies (January 2016- September 2019)
Figure 7.5: Overview of Reimbursement Policies in Europe
Figure 7.6: Market Opportunities
Figure 8.1: Neoantigen Cancer Vaccines: Heat Map
Figure 8.2: Neoantigen Cancer Vaccines: Breakdown of Pipeline by Development Phase, 2019
Figure 8.3: Neoantigen Cancer Vaccines, by Type of Therapy
Figure 8.4: Neoantigen Cancer Vaccines, by Product Type
Figure 8.5: Neoantigen Cancer Vaccines, by Treatment Strategy
Figure 8.6: Neoantigen Cancer Vaccines, by Type of Neovaccine (Biological Platform)
Figure 8.7: Neoantigen Cancer Vaccine, by Delivery Approach
Figure 8.8: Neoantigen Cancer Vaccine, by Line of Therapy
Figure 8.9: Number of Neoantigen Cancer Vaccine, by Oncology Speciality
Figure 8.10: Neoantigen Cancer Vaccine, by Route of Administration
Figure 8.11: Neoantigen Cancer Vaccines, by Core Product Status
Figure 8.12: Neoantigen Cancer Vaccines, by Payload
Figure 9.1: Share of Key Developments and Strategies, January 2016–September 2019
Figure 9.2: Synergistic Activities Share (by Company), January 2016 – September 2019
Figure 9.3: Synergistic Activities Share (by Type), January 2016–September 2019
Figure 9.4: Funding and Expansions Share (by Company), January 2016–September 2019
Figure 9.5: Merger and Acquisitions Share (by Company), January 2016–September 2019
Figure 9.6: Neoantigen Cancer Vaccine Market, by Company Status
Figure 10.1: Global Neoantigen Cancer Vaccine Market (by Product Type), 2023 vs 2030
Figure 10.2: Personalized Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 10.3: Off-the-Shelf Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 11.1: Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine), 2023 vs 2030
Figure 11.2: Nucleic Acid-based Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 11.3: Peptide Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 11.4: Dendritic Cell-Based Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 12.1: Global Neoantigen Cancer Vaccine Market (by Line of Therapy), 2023 vs 2030
Figure 12.2: First Line Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 12.3: Second Line Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 12.4: Later Lines Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 13.1: Global Neoantigen Cancer Vaccine Market (by Therapy Type), 2023 vs 2030
Figure 13.2: Neoantigen Cancer Vaccine Market (Mono Therapeutic Regimen), $Million, 2023-2030
Figure 13.3: Neoantigen Cancer Vaccine Market (Combination Therapeutic Regimens), $Million, 2023-2030
Figure 14.1: Number of Products Under Development as per Oncology Specialty, 2017-2019
Figure 14.2: Neoantigen Cancer Vaccine Market (Hematological Malignancies), $Million, 2023-2030
Figure 14.3: Neoantigen Cancer Vaccine Market (Melanoma), $Million, 2023-2030
Figure 14.4: Neoantigen Cancer Vaccine Market (Breast Cancer), $Million, 2023-2030
Figure 14.5: Neoantigen Cancer Vaccine Market (Gastrointestinal Cancer), $Million, 2023-2030
Figure 14.6: Neoantigen Cancer Vaccine Market (Lung Cancer), $Million, 2023-2030
Figure 14.7: Neoantigen Cancer Vaccine Market (Solid Tumors), $Million, 2023-2030
Figure 14.8: Neoantigen Cancer Vaccine Market (Urinary System Cancer), $Million, 2023-2030
Figure 14.9: Neoantigen Cancer Vaccine Market (Prostate Cancer), $Million, 2023-2030
Figure 14.10: Neoantigen Cancer Vaccine Market (Head and Neck Cancers), $Million, 2023-2030
Figure 14.11: Neoantigen Cancer Vaccine Market (Gynecologic Cancer), $Million, 2023-2030
Figure 14.12: Neoantigen Cancer Vaccine Market (Brain Cancer), $Million, 2023-2030
Figure 15.1: Global Neoantigen Cancer Vaccine Market Snapshot
Figure 15.2: Neoantigen Cancer Vaccine Market (by Region), $Million, 2023-2030
Figure 15.3: North America: Market Dynamics
Figure 15.4: North America Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 15.5: North America Neoantigen Cancer Vaccine Market (by Country), $Million, 2023 vs 2030
Figure 15.6: Projections of the Older Adult Population in the U.S.: 2020 to 2060 (Million)
Figure 15.7: U.S. Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.8: Canada Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.9: Europe-Market Dynamics
Figure 15.10: Europe Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 15.11: Europe Neoantigen Cancer Vaccine Market (by Country), $Million, 2023 vs 2030
Figure 15.12: Germany Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.13: France Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.14: U.K. Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.15: Italy Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.16: Spain Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.17: Rest-of-Europe Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.18: Asia-Pacific-Market Dynamics
Figure 15.19: Asia-Pacific Neoantigen Cancer Vaccine Market, $Million, 2023-2030
Figure 15.20: Asia-Pacific Neoantigen Cancer Vaccine Market (by Country), $Million, 2023 vs 2030
Figure 15.21: Japan Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.22: China Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.23: Australia Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.24: South Korea Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.25: Israel Neoantigen Cancer Vaccine Market, 2023-2030
Figure 15.26: Rest-of-Asia-Pacific Neoantigen Cancer Vaccine Market, 2023-2030
Figure 16.1: Moderna Therapeutics: Technology and Capabilities
Figure 16.2: Moderna Therapeutics: Therapeutic Focus Segmentation
Figure 16.3: Moderna Therapeutics: Overall Financials, 2016-2018
Figure 16.4: Moderna Therapeutics.: R&D Expenditure, 2016-2018
Figure 16.5: Moderna Therapeutics: SWOT Analysis
Figure 16.6: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 16.7: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 16.8: F. Hoffmann-La Roche Ltd: Revenue, by Segment, 2016-2018
Figure 16.9: F. Hoffmann-La Roche Ltd: Revenue Split for Pharmaceuticals, 2016-2018
Figure 16.10: F. Hoffmann-La Roche Ltd: Revenue, by Region, 2016-2018
Figure 16.11: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 16.12: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 16.13: AstraZeneca plc: Therapeutic Segmentation Focus
Figure 16.14: AstraZeneca plc: Overall Financials, 2016-2018
Figure 16.15: AstraZeneca plc: Net Revenue, by Region, 2016-2018
Figure 16.16: AstraZeneca plc: R&D Expense, 2016-2018
Figure 16.17: AstraZeneca: SWOT Analysis
Figure 16.18: Agenus: Technology and Capabilities (as per type of product)
Figure 16.19: Agenus: Therapeutic Focus Segmentation
Figure 16.20: Agenus: Overall Financials, 2016-2018
Figure 16.21: Agenus: R&D Expenditure, 2016-2018
Figure 16.22: Agenus: SWOT Analysis
Figure 16.23: OSE Immunotherapeutics: Therapeutic Focus Segmentation
Figure 16.24: OSE Immunotherapeutics: Overall Financials, 2016-2018
Figure 16.25: OSE Immunotherapeutics: R&D Expenditure, 2016-2018
Figure 16.26: OSE Immunotherapeutics: SWOT Analysis
Figure 16.27: Advaxis: Therapeutic Focus Segmentation
Figure 16.28: Advaxis: Overall Financials, 2016-2018
Figure 16.29: Advaxis: R&D Expenditure, 2016-2018
Figure 16.30: Advaxis: SWOT Analysis
Figure 16.31: Medigene: Therapeutic Segmentation Focus
Figure 16.32: Medigene: Overall Financials, 2016-2018
Figure 16.33: Medigene: R&D Expenditure, 2016-2018
Figure 16.34: Medigene, Inc.: SWOT Analysis
Figure 16.35: Neon Therapeutics: Therapeutic Segmentation Focus (Available from FY2019)
Figure 16.36: Neon Therapeutics: R&D Expenditure, 2016-2018
Figure 16.37: Neon Therapeutics: SWOT Analysis
Figure 16.38: Genocea Corporation: Therapeutic Focus Segmentation
Figure 16.39: Genocea Biosciences: SWOT Analysis
Figure 16.40: Immunovative Therapies: SWOT Analysis
Figure 16.41: Gritstone Oncology: Therapeutic Segmentation Focus
Figure 16.42: Gritstone Oncology: SWOT Analysis
Figure 16.43: Nouscom: Therapeutic Focus Segmentation (Available from FY2019)
Figure 16.44: Nouscom: SWOT Analysis
Figure 16.45: NantBioScience: SWOT Analysis
Figure 16.46: Immunovaccine: SWOT Analysis
Figure 16.47: BioLineRx: SWOT Analysis
The global hematology testing market was valued to be $4.54 billion in 2018 and is anticipated...
Focus on Application, Approach, Type, Line of Therapy, Treatment Strategy, Country Data (15 Countries),and Competitive Landscape – Analysis and Forecast, 2023-2030
